Taken together, these results demonstrate that cdk9 inhibition has a biological consequence in CLL cells and confirm that cdk9 inhibition is a valid anticancer therapeutic strategy. This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.